Foseal Sevelamer 400mg
Foseal 400mg is a medicine prescribed to control hyperphosphatemia in adults receiving haemodialysis or peritoneal dialysis. The active ingredient in Foseal tablets is Sevelamer hydrochloride, a phosphate binder meant for oral administration. It is used for the control of serum phosphorous in patients with chronic kidney on dialysis. Sevelamer therapy must be followed with multiple therapeutic approaches, including calcium supplements or 1,25-dihydroxy vitamin D3, to control the development of renal bone disorder.
How to use (infographics and instructions)
Follow your doctor’s advice when it comes to using Foseal 400 mg tablets. Make a call to your doctor if you have any doubt on how and when to take the tablets.
Precautions (warning, allergy, things to remember)
Do not use Foseal 400mg if you are hypersensitive to Sevelamer, have a bowel obstruction, or have hypophosphatemia. Efficacy and safety of this anti-rejection drug have not been studied in patients with:
- Active inflammatory bowel disease
- Swallowing disorders
- Patients with a history of major gastrointestinal surgery
- Gastrointestinal motility disorders including untreated or untreated or severe gastroparesis, irregular bowel motion, and retention of gastric contents. In such cases, patients should exercise caution when Foseal 400 mg tablets.
Intestinal obstruction: Rarely intestinal obstruction has been reported in patients during treatment with Sevelamer hydrochloride. Constipation may be a common symptom. Patients dealing with constipation should be monitored carefully while receiving this phosphate binding drug. The treatment should be re-evaluated in such patients or in those who have other severe gastrointestinal symptoms.
Folate deficiency: At present, there is insufficient data to exclude the possibility of folate deficiency during prolonged use.
Hypercalcaemia/hypocalcaemia: Patients suffering from renal disorder may develop hypercalcaemia or hypocalcaemia. Sevelamer does not contain calcium. Your doctor may monitor you for serum calcium levels as a normal follow up of a dialysis patient. Calcium supplements should be given in case of hypocalcaemia.
Metabolic disorders: patients are suffering from chronic kidney disorders are predisposed to developing metabolic acidosis. Worsening of metabolic acidosis have been reported upon switching from another phosphate binder to Foseal 400, where lower bicarbonate levels in the sevelamer treated patients compared to patients treated with calcium-based binders were reported.
Patients on peritoneal dialysis may develop peritonitis, an infection of your abdominal fluid associated with your peritoneal dialysis. However, one can reduce the risk by carefully adhering to the sterile methods during bag changes. In such cases, patients should inform their doctor immediately if they develop new signs of abdominal distress, abdominal pain, abdominal tenderness, swelling, constipation, abdominal rigidity, nausea, vomiting, fever, or chills. Your doctor may monitor you more carefully for problems with low levels of vitamins and folic acid.
There are reports of difficulty swallowing Foseal tablets. The drug’s safety and efficacy in children below the age of 18 years have not been studied.
Side effects of Foseal 400 mg
As mentioned above, constipation is common with Sevelamer usage, and it is especially important t inform your doctor of these symptoms before or during the treatment. Other side effects of the drug include nausea, vomiting, indigestion, diarrhoea, flatulence, hypersensitivity, and abdominal pain. If you develop any of these unwanted effects, talk to your doctor. By reporting adverse reactions, you can help provide more information on the safety of this drug.